ImaBiotech Group

Based in France, ImaBiotech Group functions as a bioanalytical Contract Research Organization, offering advanced spatial imaging solutions and comprehensive bioanalytical services throughout the drug development lifecycle. ImaBiotech Group is a bioanalytical Contract Research Organization that provides specialized services for drug development. Founded in 2009 in France, the company has focused on enhancing its offerings in response to the evolving needs of pharmaceutical and biotechnology sectors. The CEO, Jonathan Stauber, has been instrumental in guiding the company through various strategic initiatives.

In May 2021, the company was acquired by Pyxant Labs Inc. , a portfolio company of ArchiMed, marking a significant pivot in its operational strategy to enhance its services in North America. ImaBiotech Group operates as a premier bioanalytical Contract Research Organization (CRO), specializing in advanced spatial imaging solutions and bioanalytical services. The company offers a comprehensive suite of services encompassing the entire drug development lifecycle, from discovery through clinical development to New Drug Application (NDA) approval.

Their core offerings include the use of validated biomarkers, MALDI mass spectrometry imaging, and spatial omics technologies, aiming to provide high-quality data on drug efficacy and safety at a cellular level. The end users of these services include pharmaceutical and biotechnology companies, as well as academic institutions engaged in research. ImaBiotech serves clients in North America, Europe, and Asia, focusing on regulatory compliance and innovative drug development strategies. ImaBiotech Group generates revenue primarily through B2B transactions with clients in the pharmaceutical and biotechnology sectors.

Revenue streams include contracts for bioanalytical services, method development and validation, pre-clinical toxicology, and clinical development support. Partnerships facilitate access to its advanced services, priced based on the complexity and volume of services rendered. Agreements typically outline scope of work, payment terms, and deliverables, contributing to structured transaction flow. The company’s advanced spatial imaging technologies and label-free methods play a critical role in de-risking drug development projects and expediting timelines for achieving regulatory approvals.

Following its acquisition by Pyxant Labs Inc. in May 2021, ImaBiotech Group plans to expand its bioanalytical pharmaceutical services in North America, leveraging the additional resources for therapeutic innovation for its clients. The company is also exploring opportunities to launch new products designed to enhance its service offerings, with specific details on release dates yet to be disclosed.